Clinical Trials on Mild Atopic Asthma in New Zealand

Total 1238 results

Tavotek Biotherapeutics

Recruiting

A Study of TAVO101 in Atopic Dermatitis Patients

Atopic Dermatitis

New Zealand
Arrowhead Pharmaceuticals

Completed

Study of ARO-RAGE in Healthy Subjects

Asthma

New Zealand
Ribon Therapeutics, Inc.

Recruiting

SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects

Atopic Dermatitis

Australia, New Zealand
GlaxoSmithKline

Completed

A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function

Asthma

New Zealand
GlaxoSmithKline

Completed

Spacer Comparison In Adult Asthmatics

Asthma

New Zealand
GlaxoSmithKline

Completed

A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma

Asthma

New Zealand
GlaxoSmithKline

Completed

Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.

Asthma

New Zealand
GlaxoSmithKline

Completed

This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge

Asthma

New Zealand
GlaxoSmithKline

Completed

The Effect Of AVANDIA On The Late Asthmatic Response

Asthma

New Zealand
University of Otago

Completed

Does Improving Insulation and Heating Improve Health?

Asthma

New Zealand
Intech Biopharm Ltd.

Recruiting

Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma

Mild Asthma

Taiwan, India
HanAll BioPharma Co., Ltd.

Completed

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Mild to Moderate Atopic Dermatitis

United States
GlaxoSmithKline

Completed

Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate

Asthma

New Zealand
University of Southampton
National University Hospital, Singapore; Singapore Institute for Clinical Sciences and other collaborators

Enrolling by invitation

NiPPeR Randomised Trial - Child Follow Up Study (NiPPeR Child)

Neurobehavioral Manifestations | Allergy | Microbial Colonization | Growth Disorders | Atopic Dermatitis | Obesity, Childhood | Metabolic Disturbance | Cognition | Lifestyle | Breastfeeding | Nutrition, Healthy | Atopy

Singapore, United Kingdom, New Zealand
GlaxoSmithKline

Completed

A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.

Asthma

New Zealand
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
GenMont Biotech Incorporation
National Science Council, Taiwan

Completed

Probiotics and Allergic Diseases (probiotics)

Asthma | Atopic Dermatitis

Taiwan
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Facio-Scapulo-Humeral Dystrophy

New Zealand
GlaxoSmithKline

Completed

Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Asthma

United Kingdom, New Zealand
AstraZeneca

Completed

A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449

Asthma

New Zealand, United Kingdom
NeuroActiva, Inc.

Completed

A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Neurocognitive Disorders | Neurodegenerative Diseases | Cognitive Impairment | Alzheimer Disease | Tauopathies | Mild Cognitive Impairment | Dementia, Vascular | Dementia With Lewy Bodies | Alzheimer Dementia | Cognitive Disorder

New Zealand
GlaxoSmithKline

Completed

Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.

Asthma

Australia, New Zealand
Regeneron Pharmaceuticals
Sanofi

Completed

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Germany, New Zealand, Australia
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response

Asthma

Sweden, Australia, New Zealand
GlaxoSmithKline

Completed

Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing

Asthma

New Zealand, South Africa
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
Lupin, Inc.

Completed

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

Mild Persistent Asthma

United States
University of Otago

Completed

Housing, Insulation and Health Study (HIHS)

Asthma | Respiratory Illness

New Zealand
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

Myotonic Dystrophy 1

New Zealand, Australia
Naestved Hospital

Recruiting

Implementation of Evidence-based Breathing Retraining for Patients With Asthma in Region Zealand (EmBRAiZ)

Asthma

Denmark
Akesobio Australia Pty Ltd

Recruiting

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, New Zealand
Allergan

Completed

Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis

Atopic Conjunctivitis

Canada, Czech Republic, United States, Italy, Israel, New Zealand, Spain, India, Germany, Australia, France, United Kingdom
CuraSen Therapeutics, Inc.

Active, not recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011)

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

Australia, New Zealand, United Kingdom
Botanix Pharmaceuticals

Completed

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Australia, New Zealand
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Shaperon

Recruiting

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp

United States
MedImmune LLC
Amgen

Completed

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis (ALLEVIAD)

Atopic Dermatitis

United States, Germany, New Zealand, Hungary, Australia, Canada
Equillium
Biocon Limited; Equillium AUS Pty Ltd

Completed

A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma (EQUIP)

Asthma

New Zealand, Australia
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
AnaptysBio, Inc.

Recruiting

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).

Atopic Dermatitis Eczema

Georgia, United States, Australia, Canada, Czechia, New Zealand, Poland
Intellia Therapeutics

Recruiting

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Wild-Type Transthyretin Cardiac Amyloidosis

United Kingdom, New Zealand, Sweden
Johnson & Johnson Consumer Inc. (J&JCI)

Completed

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

Atopic Dermatitis (AD)

United States
Qurient Co., Ltd.

Completed

Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Moderate to Severe Atopic Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Atopic Dermatitis (AD)

United States, Canada
University of Western Sydney

Completed

Memory Encoding Strategies for People With Mild Cognitive Impairments

Mild Cognitive Impairment | Mild Dementia

Hong Kong, Australia
Inmagene LLC

Terminated

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis | Moderate-to-severe Atopic Dermatitis | AD

Canada, United States
Arrowhead Pharmaceuticals

Recruiting

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Asthma

Korea, Republic of, Australia, Thailand, New Zealand, Poland, Spain
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (DISCOVER)

Moderate-to-Severe Atopic Dermatitis | Atopic Eczema

United States
Numab Therapeutics AG
Kaken Pharmaceutical Co., Ltd.

Recruiting

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Atopic Dermatitis

Germany, Canada, United States, Poland
CuraSen Therapeutics, Inc.

Completed

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

Dementia | Mild Cognitive Impairment

United States, New Zealand

Clinical Trials on Mild Atopic Asthma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations